GlassScriptPhysician profile
Santiago E Encalada
NPI 1184989428
$1,770.87
in general payments reported to CMS, 2019-2025
22 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $86.72 · 2021: $192 · 2022: $641 · 2023: $93.71 · 2024: $91.54 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.11 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.57 | 2019-2025 | Fasenra, Tezspire |
| Gilead Sciences, INC. | $213.88 | 2019-2021 | |
| Mylan Specialty L.P. | $174.26 | 2021-2022 | |
| Genzyme Corporation | $123.53 | 2019-2021 | |
| Baxter Healthcare | $123.51 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Vertex Pharmaceuticals Incorporated | $96.80 | 2019-2022 | |
| Philips North America LLC | $91.91 | 2019-2024 | (Ak6) Vest Therapy |
| Biofire Diagnostics, LLC | $90.01 | 2019 | |
| Chiesi USA, INC. | $76.83 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $57.44 | 2022-2023 | Dupixent |
| Viatris Specialty LLC | $53.16 | 2025 | Tobi Podhaler |
| Advanced Respiratory, INC | $48.93 | 2019-2021 | |
| Digestive Care, INC. | $37.65 | 2024 | Pertzye |
| Electromed, INC. | $29.73 | 2023 | Smartvest |
| Allergan, INC. | $26.59 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.82 | 2019 | |
| Vivus LLC | $18.99 | 2021 | |
| Aimmune Therapeutics, INC. | $17.83 | 2025 | Zenpep |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Phadia US INC. | $14.97 | 2019 | |
| Masimo Corporation | $13.57 | 2022 | |
| Vyaire Medical, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santiago Encalada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.